RecruitingPhase 2Drug trialCBD for Individuals at Risk for Alzheimer's DiseaseThis is a double-blind, randomized controlled trial designed to test the effects of cannabidiol (CBD) on validated biomarkers of Alzheimer's disease (AD) progression, and behavioral, neurocognitive, and clinical measures, with putative mechanisms of action.